Largest biotech companies in the United States by net assets
Shareholders' equity at the end of the latest fiscal year: what the company owns less what it owes. A negative figure means it owes more than it owns.
Gilead Sciences leads the 20 biotech companies in the United States ranked by net assets, at SAR 85.2B, ahead of Biogen (SAR 68.5B) and Amgen (SAR 32.5B). Figures as of 20 Nov 2026, 06:46 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 20
- First
- Gilead SciencesSAR 85.2B
- Median
- SAR 6B
- Combined market value
- SAR 2.76T
- Countries
- 1
Market values as of .
United States▾
All sectors▾
Biotech▾
| # | Company | Net assets ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | Gilead SciencesGILD · Health Care | SAR 85.2B | SAR 774.9B | SAR 624.74 | 1.45% down | 35% up | ||
| 2 | BiogenBIIB · Health Care | SAR 68.5B | SAR 137B | SAR 927.11 | 1.70% down | 49% up | ||
| 3 | AmgenAMGN · Health Care | SAR 32.5B | SAR 890.5B | SAR 1,646.23 | 1.14% down | 32% up | ||
| 4 | ModernaMRNA · Health Care | SAR 32.5B | SAR 302.6B | SAR 747.79 | 1.29% up | 780% up | ||
| 5 | Neurocrine BiosciencesNBIX · Health Care | SAR 12.2B | SAR 59.5B | SAR 587.45 | 3.85% down | 17% up | ||
| 6 | VaxcytePCVX · Health Care | SAR 10.1B | SAR 34.7B | SAR 218.94 | 0.27% down | 23% up | ||
| 7 | ExelixisEXEL · Health Care | SAR 8.1B | SAR 60.3B | SAR 246.96 | 3.60% down | 63% up | ||
| 8 | Bio-TechneTECH · Health Care | SAR 7.9B | SAR 42.8B | SAR 272.73 | 0.07% down | 24% up | ||
| 9 | RepligenRGEN · Health Care | SAR 7.9B | SAR 40.8B | SAR 638.84 | 1.38% down | 12% up | ||
| 10 | Revolution MedicinesRVMD · Health Care | SAR 6.1B | SAR 129.4B | SAR 598.10 | 0.24% down | 129% up | ||
| 11 | Kymera TherapeuticsKYMR · Health Care | SAR 5.9B | SAR 38.2B | SAR 447.89 | 1.44% down | 87% up | ||
| 12 | Krystal BiotechKRYS · Health Care | SAR 4.6B | SAR 35.1B | SAR 1,184.80 | 0.15% up | 54% up | ||
| 13 | ImmunovantIMVT · Health Care | SAR 3.2B | SAR 25.2B | SAR 122.00 | 1.96% down | 46% up | ||
| 14 | CG OncologyCGON · Health Care | SAR 2.8B | SAR 27.4B | SAR 307.25 | 2.38% up | 97% up | ||
| 15 | Twist BioscienceTWST · Health Care | SAR 1.8B | SAR 28.5B | SAR 418.74 | 4.07% down | 346% up | ||
| 16 | Scholar Rock HoldingSRRK · Health Care | SAR 920.9M | SAR 23.1B | SAR 188.96 | 4.94% up | 26% up | ||
| 17 | Adaptive BiotechnologiesADPT · Health Care | SAR 820.8M | SAR 17B | SAR 105.23 | 1.44% down | 74% up | ||
| 18 | Kodiak SciencesKOD · Health Care | SAR 590.4M | SAR 24B | SAR 367.27 | 0.09% up | 399% up | ||
| 19 | Halozyme TherapeuticsHALO · Health Care | SAR 183.1M | SAR 39.8B | SAR 349.04 | 2.88% down | 39% up | ||
| 20 | ImmunityBioIBRX · Health Care | -SAR 1.9B | SAR 26.2B | SAR 24.65 | 1.94% down | 232% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Net assets is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Sums are converted from US dollars at today's exchange rate (1 USD = 3.7515 SAR).
Questions and answers
Which biotech companies in the United States rank first by net assets?
Gilead Sciences (SAR 85.2B), Biogen (SAR 68.5B) and Amgen (SAR 32.5B) are the top three of the 20 biotech companies in the United States ranked by net assets as of 20 Nov 2026, 06:46 UTC.
How many biotech companies in the United States are in this ranking?
20 are ranked by net assets.
What are these biotech companies in the United States worth together?
The 20 biotech companies in the United States ranked by net assets have a combined market value of SAR 2.76T as of 20 Nov 2026, 06:46 UTC.
What does ranking by net assets measure?
Shareholders' equity at the end of the latest fiscal year: what the company owns less what it owes. A negative figure means it owes more than it owns.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest biotech companies in the United States by net assets”, data as of 20 November 2026. https://funkfolio.com/companies/category/biotech?country=united-states&by=net-assets
Underlying data: Yahoo Finance; SEC EDGAR.